The acquired immunodeficiency syndrome (AIDS), a condition in which the immune system gradually fails and life-threatening opportunistic infections and cancers proliferate, is brought on by the lentivirus (a subgroup of retrovirus) known as HIV. HIV infection happens when blood, semen, vaginal fluid, pre-ejaculate, or breast milk are shared. HIV can be found in these bodily fluids as both free virus particles and as a virus inside infected immune cells.Important immune system components like helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells are all infected by HIV. Apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells are some of the mechanisms by which HIV infection results in low levels of CD4+ T cells. Cell-mediated immunity is lost and the body becomes progressively more vulnerable to opportunistic infections when CD4+ T cell counts fall below a critical threshold.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V51988 | HIV-1 capsid inhibitor 1 | 2396382-78-6 | HIV-1 capsid inhibitor 1 is a potent HIV-1 Capsid inhibitor (antagonist) with EC50 of 3.13 µM. | |
V57504 | HIV-1 gag Protein p24 (194-210) | 141281-67-6 | HIV-1 gag Protein p24 (194-210) is a bioactive peptide discovered by peptide screening. | |
V54246 | HIV-1 inhibitor-10 | 1449660-81-4 | HIV-1 inhibitor-10 is a nanomolar inhibitor of HIV-1 maturation. | |
V76169 | HIV-1 inhibitor-13 | 2761172-60-3 | HIV-1 inhibitor-13 (compound 16c) is an orally bioactive HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 0.14 μM (HIV-1 RT). | |
V76179 | HIV-1 inhibitor-14 | 2761172-65-8 | HIV-1 inhibitor-14 (compound 14b) is a highly efficient and broad-spectrum HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor (antagonist) with IC50 of 0.14 μM for HIV-1 RT. | |
V76177 | HIV-1 inhibitor-17 | 2764787-76-8 | HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor (antagonist) with EC50 of 2.57 μM against HIV-1 NL4-3 strain. | |
V76173 | HIV-1 inhibitor-18 | 2764787-56-4 | HIV-1 inhibitor-18 (compound II-13c) is a potent HIV-1 capsid inhibitor (antagonist) with EC50 of 5.14 μM against HIV-1 NL4-3 strain. | |
V53323 | HIV-1 inhibitor-48 | 374067-85-3 | HIV-1 inhibitor-48 (compound 13o) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with anti-HIV (Human Immunodeficiency Virus)-1 activity. | |
V51987 | HIV-1 inhibitor-50 | 2834087-69-1 | HIV-1 inhibitor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 reverse transcriptase (RT) (IC50=50 nM). | |
V54263 | HIV-1 inhibitor-51 | 2834087-82-8 | HIV-1 inhibitor-51 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that displays excellent antiviral effect against WT HIV-1 (IIIB) and a panel of mutant strains. | |
V54298 | HIV-1 inhibitor-52 | 1818868-23-3 | HIV-1 inhibitor-52 is an effective broad-spectrum HIV-1 activity inhibitor, effective against WT HIV-1, HIV-1 V370A, HIV-1 ΔV370, HIV-1 V362I/V370A, HIV-1 T332S/V362I/ The EC50 of prR41G, HIV-1 A326T/V362I/V370A, HIV-1 R361K/V362I/L363M is 1.6 nM-6.4 nM. | |
V51985 | HIV-1 inhibitor-54 | 2771211-71-1 | HIV-1 inhibitor-54 is a potent HIV-1 inhibitor. | |
V51984 | HIV-1 inhibitor-55 | 2771211-73-3 | HIV-1 inhibitor-55 (compound 4d) inhibits WT HIV-1 with EC50 of 8.6 nM. | |
V54286 | HIV-1 inhibitor-56 | 2952530-45-7 | HIV-1 inhibitor-56 (compound 12126065) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor. | |
V54296 | HIV-1 inhibitor-57 | 2745197-24-2 | HIV-1 inhibitor-57 (Compound 12g) is an HIV inhibitor. | |
V78495 | HIV-1 inhibitor-59 | HIV-1 inhibitor-59 (Compound I-5b) is an HIV-1 inhibitor (antagonist) with EC50 of 5.62-171 nM against wild-type (WT) and HIV-1 mutant strains. | ||
V85386 | HIV-1 inhibitor-61 | 1114507-62-8 | ||
V84790 | HIV-1 inhibitor-62 | |||
V84257 | HIV-1 inhibitor-63 | |||
V83480 | HIV-1 inhibitor-64 | 2919019-36-4 |